CooperCompanies Appoints Walt Rosebrough as Independent Director to Enhance Long-Term Value
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy COO?
Source: Globenewswire
- New Board Member: CooperCompanies has appointed Walt Rosebrough as an independent director effective January 3, 2026, aiming to leverage his extensive experience in the medical device industry to drive strategic growth.
- Governance Structure Enhancement: Rosebrough will join the Board's Corporate Governance & Nominating Committee and is expected to be considered for the Chair position by the end of 2026, indicating the company's focus on governance and future leadership planning.
- Cooperation Agreement Established: CooperCompanies has entered into a cooperation agreement with investment partner Browning West, which will support the Board's full slate of directors at the 2026 Annual Meeting, ensuring stability and consistency in governance.
- Long-Term Value Commitment: The co-founder of Browning West stated that Rosebrough's appointment will help CooperCompanies drive critical initiatives to unlock sustained long-term value, reflecting the company's confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 81.700
Low
73.00
Averages
90.33
High
100.00
Current: 81.700
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
Boyar Research Unveils 2026's 'Forgotten Forty' Stocks with High Upside Potential
- Undervalued Stocks: Boyar Research's 'Forgotten Forty' list includes stocks like Uber and Airbnb, which are expected to outperform the market in the coming year, reflecting renewed investor interest in value stocks.
- Tax Law Impact: Atlanta Braves Holdings faces a tax law change effective in 2027 that limits deductions for top executives, potentially reducing profitability and prompting owner John Malone to consider selling the team to mitigate tax implications.
- Market Potential: Markel Group, dubbed the 'baby Berkshire', is under activist pressure to unlock value through share buybacks and operational improvements, with a current share price around $2,000 and an estimated worth of $3,100, indicating strong growth potential.
- Business Split Expectations: Cooper Companies, with a 25% market share in contact lenses, is facing calls for a split to optimize capital allocation, which analysts believe will enhance overall business performance and drive stock price increases.
See More
CooperVision Launches MyDay® MiSight® 1 Day Contact Lenses for Myopia Control
- Market Expansion: CooperVision is set to launch MyDay® MiSight® 1 Day contact lenses in the UK and select European markets, aiming to meet the growing demand for myopia control by combining ActivControl® technology with modern silicone hydrogel materials, which is expected to significantly enhance the company's market share in pediatric vision correction.
- Technological Innovation: The new lenses utilize ActivControl® technology, which has been shown to reduce myopia progression by approximately 50%, providing more effective vision protection for millions of children and further solidifying CooperVision's leadership position in the eye care industry.
- Enhanced User Experience: The design of MyDay® MiSight® 1 Day lenses includes corrective and therapeutic zones, ensuring users achieve clear vision while effectively controlling myopia progression, which is anticipated to boost customer satisfaction and brand loyalty.
- Strategic Commitment: CooperVision's Commercial Director, Debbie Olive, stated that the company is unwavering in its commitment to addressing myopia both scientifically and commercially; the launch of this new product not only reflects technological advancement but also a long-term commitment to children's eye health, expected to drive future sales growth.
See More
CooperVision Launches MyDay® MiSight® 1-Day Contact Lenses, Reducing Myopia Progression by 50%
- Product Innovation: CooperVision has launched MyDay® MiSight® 1-Day contact lenses, integrating ActivControl® technology with advanced silicone hydrogel materials to slow myopia progression in children, which is expected to significantly enhance children's quality of life.
- Market Expansion: The new product will be available in the UK and selected European markets, addressing the growing demand for myopia control in children, thereby strengthening CooperVision's competitive position in the ophthalmic market.
- Clinical Validation: The ActivControl® technology has been clinically proven to reduce myopia progression by approximately 50% in long-term studies, which will enhance parental trust in the product and drive sales growth.
- Strategic Goals: CooperVision is committed to addressing childhood myopia through both scientific and commercial means, and this product launch aligns with its long-term vision to capture growth opportunities in the global children's vision health market.
See More
CooperVision Launches MyDay®MiSight®1 Day Contact Lenses, Slowing Myopia Progression by 50%
- Innovative Product Launch: CooperVision announced the upcoming launch of MyDay®MiSight®1 day contact lenses in the UK and surrounding markets, combining advanced silicone hydrogel material with ActivControl® technology to slow myopia progression in children, which is expected to significantly enhance children's quality of life.
- Market Demand Response: With one in two newborns potentially becoming myopic by age 20, the product launch not only addresses the urgent market need for myopia management but also enhances the company's competitive edge by providing effective solutions.
- Clinical Support: The ActivControl® technology has been clinically proven to reduce myopia progression by approximately 50%, providing strong evidence for the new product's efficacy, which is likely to attract more parents to choose these contact lenses.
- Long-term Strategic Positioning: This product launch aligns with CooperVision's global market expansion strategy, aiming to solidify its leadership position in the contact lens industry through continuous innovation and scientific research.
See More
CooperVision Launches MyDay® MiSight® 1-Day Contact Lenses to Combat Myopia in Children
- New Product Launch: CooperVision is set to introduce MyDay® MiSight® 1-Day contact lenses in the UK and select European markets, combining advanced silicone hydrogel material with ActivControl® technology to effectively slow myopia progression in children, which is expected to significantly enhance market competitiveness.
- Technological Advantage: The ActivControl® technology has been shown to reduce myopia progression by approximately 50% in children, providing millions with better vision solutions that enhance their quality of life and learning capabilities.
- Market Demand: With one in two newborns potentially developing myopia by age 20, this new product from CooperVision directly addresses the growing market demand for myopia control in children, likely driving further growth in the company's eye care segment.
- Strategic Positioning: By launching MyDay® MiSight® 1-Day contact lenses, CooperVision not only demonstrates its leadership in myopia control but also reaffirms its long-term commitment to children's eye health, further solidifying its influence in the global market.
See More
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
Boyar Research Unveils 2026's 'Forgotten Forty' Stocks with High Upside Potential
- Undervalued Stocks: Boyar Research's 'Forgotten Forty' list includes stocks like Uber and Airbnb, which are expected to outperform the market in the coming year, reflecting renewed investor interest in value stocks.
- Tax Law Impact: Atlanta Braves Holdings faces a tax law change effective in 2027 that limits deductions for top executives, potentially reducing profitability and prompting owner John Malone to consider selling the team to mitigate tax implications.
- Market Potential: Markel Group, dubbed the 'baby Berkshire', is under activist pressure to unlock value through share buybacks and operational improvements, with a current share price around $2,000 and an estimated worth of $3,100, indicating strong growth potential.
- Business Split Expectations: Cooper Companies, with a 25% market share in contact lenses, is facing calls for a split to optimize capital allocation, which analysts believe will enhance overall business performance and drive stock price increases.
See More
CooperVision Launches MyDay® MiSight® 1 Day Contact Lenses for Myopia Control
- Market Expansion: CooperVision is set to launch MyDay® MiSight® 1 Day contact lenses in the UK and select European markets, aiming to meet the growing demand for myopia control by combining ActivControl® technology with modern silicone hydrogel materials, which is expected to significantly enhance the company's market share in pediatric vision correction.
- Technological Innovation: The new lenses utilize ActivControl® technology, which has been shown to reduce myopia progression by approximately 50%, providing more effective vision protection for millions of children and further solidifying CooperVision's leadership position in the eye care industry.
- Enhanced User Experience: The design of MyDay® MiSight® 1 Day lenses includes corrective and therapeutic zones, ensuring users achieve clear vision while effectively controlling myopia progression, which is anticipated to boost customer satisfaction and brand loyalty.
- Strategic Commitment: CooperVision's Commercial Director, Debbie Olive, stated that the company is unwavering in its commitment to addressing myopia both scientifically and commercially; the launch of this new product not only reflects technological advancement but also a long-term commitment to children's eye health, expected to drive future sales growth.
See More
CooperVision Launches MyDay® MiSight® 1-Day Contact Lenses, Reducing Myopia Progression by 50%
- Product Innovation: CooperVision has launched MyDay® MiSight® 1-Day contact lenses, integrating ActivControl® technology with advanced silicone hydrogel materials to slow myopia progression in children, which is expected to significantly enhance children's quality of life.
- Market Expansion: The new product will be available in the UK and selected European markets, addressing the growing demand for myopia control in children, thereby strengthening CooperVision's competitive position in the ophthalmic market.
- Clinical Validation: The ActivControl® technology has been clinically proven to reduce myopia progression by approximately 50% in long-term studies, which will enhance parental trust in the product and drive sales growth.
- Strategic Goals: CooperVision is committed to addressing childhood myopia through both scientific and commercial means, and this product launch aligns with its long-term vision to capture growth opportunities in the global children's vision health market.
See More
CooperVision Launches MyDay®MiSight®1 Day Contact Lenses, Slowing Myopia Progression by 50%
- Innovative Product Launch: CooperVision announced the upcoming launch of MyDay®MiSight®1 day contact lenses in the UK and surrounding markets, combining advanced silicone hydrogel material with ActivControl® technology to slow myopia progression in children, which is expected to significantly enhance children's quality of life.
- Market Demand Response: With one in two newborns potentially becoming myopic by age 20, the product launch not only addresses the urgent market need for myopia management but also enhances the company's competitive edge by providing effective solutions.
- Clinical Support: The ActivControl® technology has been clinically proven to reduce myopia progression by approximately 50%, providing strong evidence for the new product's efficacy, which is likely to attract more parents to choose these contact lenses.
- Long-term Strategic Positioning: This product launch aligns with CooperVision's global market expansion strategy, aiming to solidify its leadership position in the contact lens industry through continuous innovation and scientific research.
See More
CooperVision Launches MyDay® MiSight® 1-Day Contact Lenses to Combat Myopia in Children
- New Product Launch: CooperVision is set to introduce MyDay® MiSight® 1-Day contact lenses in the UK and select European markets, combining advanced silicone hydrogel material with ActivControl® technology to effectively slow myopia progression in children, which is expected to significantly enhance market competitiveness.
- Technological Advantage: The ActivControl® technology has been shown to reduce myopia progression by approximately 50% in children, providing millions with better vision solutions that enhance their quality of life and learning capabilities.
- Market Demand: With one in two newborns potentially developing myopia by age 20, this new product from CooperVision directly addresses the growing market demand for myopia control in children, likely driving further growth in the company's eye care segment.
- Strategic Positioning: By launching MyDay® MiSight® 1-Day contact lenses, CooperVision not only demonstrates its leadership in myopia control but also reaffirms its long-term commitment to children's eye health, further solidifying its influence in the global market.
See More
